In subsequent studies, FOXD2-AS1 was also identified to be associated with poor prognosis in esophageal squamous cell carcinoma, nasopharyngeal carcinoma and bladder cancer by regulating the proliferation, apoptosis, migration and invasion of tumor cells, suggesting that it may function as a biomarker or a potential target for cancer intervention [11,12,13]. This evidence concerns the gene FOXD2 and esophageal squamous cell carcinoma.